Upload
mauricio-lema
View
313
Download
0
Embed Size (px)
Citation preview
CES 2016.02: Lower Gastrointestinal Cancers
Mauricio Lema Medina MD
Mauricio Luján Piedrahíta, MD
Acknowledgments
Second cause of cancer death in the USThe incidence has decreased recently (in the US) due to screening
Mortality has decreased by about 25%
POLYPSGrossly visible protrusion fro the mucosal surface
Nonneoplastic hamartomaHyperplastic mucosal proliferation (hyperplastic polyp)
Adenomatous polypsClearly preneoplastic
Only a minority of polyps progress to cancerHigh prevalence: 30% and 50% in middle-aged and elderly adults
Only 1% become malignant
Multistep molecular evolution through cancerColon cancer is thought to arise from sequential DNA derrangements in a polyp
These may include: Point mutations in the K-ras (KRAS) oncogeneHypomethylation of DNA
Allelic loss of a TSG like 5q (APC), 18q (DCC), 17p (p53)
Oncogene activationLoss of tumor suppression activity
Multi-stage carcinogenesis in colon cancer
Inspired on: Vogelstein B, 1990
MAPK pathway (activating) mutations occur in about 60% CRC
KRAS: 40-50%NRAS: 10%
BRAF: 8%
POLYPS
PedunculatedFlat-based: sessileHigher risk of cancer development
TubularVillous
TubulovillousHigher risk of cancer development (3x)
Small (1.5 cm, or less)Intermediate (1.5-2.5 cm)
Substantial (2.5 cm, or more)(2-10% cancer risk)
(10% cancer risk or more)
The entire bowel should be visualized (1-3 risk of synchronous polyps).Follow-up with colonoscopies: 30-50% risk of another adenoma
Adenomas become cancer in about 5 yearsColonoscopy need not be more frequent than every 3 years
Once a poly is found
Risk factors for the development of colorectal cancer
Diet: animal fat Hereditary syndromes
Inflammatory bowel diseaseStreptococcus bovis bacteremia
Upper socioeconomic populations
Correlates with per capita consumption of calories,meat protein, dietary fat and oil, high cholesterol,
high coronary artery disease
Dietary fats change in the microbiome (anaerobes), converting bile-acids into carcinogens
High-calorie intake / inactivity cause obesity: insulin resistance, increase in IGF-1, more
polyps (and cancer)
Fibers and vegetable intake have no been proven to prevent CRC development
Up to 25% have a family historyPolyposis coli
MYH-associated polyposisNonpolyposis syndromes (Lynch)
More with ulcerative colitisRare during first 10 years
Thereafter: 1%/yr incidenceProphylactic colectomy for long active IBD
For unknown reasonConsider upper and lower GI endoscopies
Hereditary syndromesPolyposis coli
Thousands of adenomatous polyps through the large bowelAutosomal dominant
Deletion of 5qLoss of the APC gene (a TSG)
Gardner’s syndromeSoft-tissue and bony tumors
Congenital hypertrophy of the retinal epitheliumMesenteric desmoid tumors
Ampullary carcinomasPolyposis coli
Turcot’s syndromeMalignant tumors of the Central Nervous system
Polyposis coli
Polyps are rare before pubertyBut are detectable in most by age 25
Cancer will develop in (almost) all by 40
Once multiple polyps develop, total colectomy must be performedOffspring of affected patients have 50% risk of disease
Flexible sigmoidoscopy until 35 should be performedGerm-line APC mutation detection should be considered
Hereditary syndromes
Hereditary nonpolyposis colon cancer (HNPCC) - Lynch’s syndrome
Three or more relatives with documented colorectal cancer;one who is a first-degree relative of the other two;
CRC before 50 in at least one;Spanning at least 2 generations.
Autosomal dominantMedian-age at CRC diagnosis: less than 50
Screening colonoscopy starting on age 25 (q1 to 2 years), with pelvic US/endometrial biopsy for women
Poorly-differentiatedMucinous histologies
Right-sided preferenceBETER PROGNOSIS
Association with other malignancies (in the family)Ovarian or endometrial carcinomas in women
Gastric, small-bowel, pancreaticobiliary, genitourinary cancerssebaceus skin tumors
Lynch’s syndrome is associated with mutations of several geneshMSH2 (chromosome 2)
hMLH1 (chromosome 3), and others
Unable to repair DNA mismatches (MMR)High frequency of microsatellite instability
Colorectal cancer: presenting symptoms
Right-sided colon tumors May be very large without symptomsIron-deficiency anemia is characteristic
Left-sided tumorsAbdominal crampingIntestinal obstructionIntestinal perforation
Rectosigmoid tumorsHematochezia
tenesmusnarrowing of the caliber of stool
(similar to hemorrhoids)Anemia is rare
CRC: Staging, prognostic factors, and pattern of spread
Harrison’s, 19th Ed.
Predictors of poor outcome following total surgical resection in CRC
Tumor spread to regional lymph nodes
Number of lymph nodes involved
Tumor penetration to through the bowel wall
Poorly differentiated histology
Perforation
Tumor adherence to adjacent organs
Venous invasion
Preoperative CEA elevation
AneuploidySpecific chromosomal deletion (BRAF mutation, absence of MSI)
CRC: Staging, prognostic factors, and pattern of spread
Harrison’s, 19th Ed.
Adenocarcinoma
CRC: Staging
AJCC TNM, 7th Ed, 2010
CRC: Staging
AJCC TNM, 7th Ed, 2010
CRC: Staging, prognostic factors, and pattern of spread
Harrison’s, 19th Ed.
High-risk stage II
T4
Perforation
Obstruction
Lymphovascular invasion
non-R0 resection
Less than 12 lymph nodes evaluated
High-risk recurrence score (in MSS)
CRC: pattern of spread
Harrison’s, 19th Ed.
Most recurrences occur within 4 years of surgery
At least 12 lymph nodes need to be evaluated to establish prognosis
TNM/Stage is prognostic
Regionallymph nodes
Supraclavicular
lymph nodesVia the portal venous
system
Liver metastasesInitial site of spread in 1/3Involved at death in 2/3
Distal rectum:
paravertebral venous
plexus
Median survival of metastatic CRC is improving: about 2-3 years (2016)
CRC: Treatment
Harrison’s, 19th Ed.
Pre-surgical work-up
H&P
Basic labs, including LFTs, CEA
Thorax, abdomen and pelvis contrast-enhanced CT
Full-length colonoscopy
Surgery
Colectomy with regional lymph-node dissectionTotal mesorectal excision for rectal cancer with regional lymph-node
dissectionAt least 12 lymph-nodes need to be assessed
Surgery in symptomatic patients, regardless of metastasesAdequate surgical margins needed to avoid recurrence in the
anastomotic site
CRC: Treatment
Harrison’s, 19th Ed.
Colon cancer (non-rectal)
Surgery
Stage I
Follow-up
Low-Risk Stage II
Follow-up
High-Risk Stage II/Stage III
Stage IVaResectable
Stage IVaConvertible
Stage IVb
Surgery
ChemoT PalliativeCT
Follow-up Follow-up Follow-up
AdjChemoT
Surgery
AdjChemoT
Surgery Surgery
CRC: Treatment
Harrison’s, 19th Ed.
Adjuvant chemotherapy in colon cancer
Ideally, start within 1 month of surgery, for 6 months
Improves survival by 30% in stage III CRC patients
May improve survival in high-risk stage II colon cancer patients
Based on Fluorouracil (5-FU)
Infusional 5-FU both more effective, and less toxic, than bolus
Modulation with Folinate (Leucovorin, LV) improves outcomes
Addition of Oxaliplatin improves DFS and OS in stage III patients (ie, FOLFOX)
Unclear benefit of Oxaliplatin in stage II and older than 70
No benefit of adjuvant 5-FU alone in stage II patients with microsatellite instability
CRC: Treatment
Harrison’s, 19th Ed.
Rectal cancer
Surgery
Stage I
Follow-up
Low-Risk Stage II
Follow-up
High-Risk Stage II/Stage III
Stage IVaResectable
Stage IVaConvertible
Stage IVb
Surgery
ChemoT PalliativeCT
Follow-up Follow-up Follow-up
AdjChemoT
Surgery
AdjChemoT
Surgery Surgery
ChemoRT ChemoRT
ChemoRT
ChemoRT
Pelvic radiation (with radiosensitizing chemotherapy) decreases local-recurrence, but has no impact in overall survival in rectal cancer
AdjChemoT
CRC: Treatment
Harrison’s, 19th Ed.
Adjuvant chemotherapy in rectal cancer
Ideally, start within 1 month of surgery, for 6 months
Improves survival in stage II-III CRC patients
Based on Fluorouracil (5-FU)
Infusional 5-FU both more effective, and less toxic, than bolus
Modulation with Folinate (Leucovorin, LV) improves outcomes
Unclear benefit of Oxaliplatin in stage II and older than 70
Oxaliplatin reasonable in high-risk stage II rectal cancer (ie, FOLFOX)
No benefit of adjuvant 5-FU alone in stage II patients with microsatellite instability
CRC: Treatment
Harrison’s, 19th Ed.
Systemic therapy for metastatic CRC
5-FU-based (or Capecitabine)
Each, oxaliplatin and irinotecan improve overall survival
Bevacizumab increases overall survival in first- and second-line always with CT
Other antiangiogenic agents can be used in second-line (aflibercept, ramicirumab)
Anti-EGFR agents are active as single-agents and combination in unmutated RAS
Left-sided colon cancer appear to derive greater benefit from anti-EGFR therapy
Multikinase inhibitors may afford benefit after all other agents have been used
With current therapies, median overall survival for metastatic CRC is abotu 39 mo
CRC: Clinical pathway - stage III colon cancer
Screening
SymptomsColonoscopy / Biopsy Staging
CT/CEA/labs Surgery 6 months adjuvant CT (ie, FOLFOX)
CRC: Clinical pathway - stage III colon cancer
Screening
SymptomsColonoscopy / Biopsy Staging
CT/CEA/labs Surgery 6 months adjuvant CT (ie, FOLFOX)
CRC: Clinical pathway - Stage II/III rectal cancer
Surgery 4-6 months adjuvant CT (ie, 5-FULV/FOLFOX)
ChemoRT(ie, 5FU/LV)
CRC: Clinical pathway - stage III colon cancer
Screening
SymptomsColonoscopy / Biopsy Staging
CT/CEA/labs Surgery 6 months adjuvant CT (ie, FOLFOX)
CRC: Clinical pathway - Stage II/III rectal cancer
Surgery 4-6 months adjuvant CT (ie, 5-FULV/FOLFOX)
ChemoRT(ie, 5FU/LV)
CRC: Clinical pathway - Stage IVb CRC mutated RAS
BevacizumabFOLFIRI
BevacizumabFOLFOX Regorafenib
CRC: Clinical pathway - stage III colon cancer
Screening
SymptomsColonoscopy / Biopsy Staging
CT/CEA/labs Surgery 6 months adjuvant CT (ie, FOLFOX)
CRC: Clinical pathway - Stage II/III rectal cancer
Surgery 4-6 months adjuvant CT (ie, 5-FULV/FOLFOX)
ChemoRT(ie, 5FU/LV)
CRC: Clinical pathway - Stage IVb CRC mutated RAS
BevacizumabFOLFIRI
BevacizumabFOLFOX Regorafenib
CRC: Clinical pathway - Stage IVb CRC mutated RAS
CetuximabFOLFIRI
BevacizumabFOLFOX Regorafenib
CRC: Follow-up
Harrison’s, 19th Ed.
Post-treatment follow-up
3-5% life-time risk of a second CRC, 15% risk of polyps
5-year follow-up
H&P q12w x2-3 years. Thereafter, semi-annually until year 5
Triennial colonoscopy
CEA q12w x2-3 years. Thereafter, semi-annually until year 5
Contrast-enhanced thorax, abdomen and pelvis CT q1yr until year 3
CRC: Prognosis